title: [Specific expression in brain of exogenous gene by transpassing blood-brain barrier after intravenous injection].
abstract: OBJECTIVE
  To study the expression of exogenous LacZ gene in brain via a delivery of OX26-pGFAP-IL.
  
  
  METHODS
  pCMV-Liposome, OX26-pCMV-IL, OX26-pGFAP-IL and blank liposome were injected into rats via femoral vein. At 24 h post-injection, the method of Q-PCR was adopted to calculate the relative quantities of LacZ gene mRNA in brain and peripheral organs. At 48 h post-injection, the protein expression of LacZ gene was detected by the activity of beta-galactosidase and the method of histochemical stain.
  
  
  RESULTS
  The result of Q-PCR showed that, at 24 h post-injection, the relative quantities of LacZ mRNA in OX26-pCMV-IL group (49.2 x 10(-6)) and OX26-pGFAP-IL group (44.9 x 10(-6)) were significantly higher than pCMV-liposome and blank liposome groups (P < 0.05). In peripheral organs, the relative quantity of LacZ mRNA in OX26-pCMV-IL group were significantly higher than that in OX26-pGFAP-IL group (P < 0.05). At 48 h post-injection, the activity of beta-galactosidase in OX26-pCMV-IL (0.67 pg/mg) and OX26-pGFAP-IL groups (0.92 pg/mg) were significantly higher than pCMV-liposome and blank liposome groups (P < 0.05). There was no significant difference between OX26-pCMV-IL group and OX26-pGFAP-IL group in terms of the expression of beta-galactosidase. The result of histochemical stain showed that OX26-pGFAP-IL achieved a specifically positive expression in brain and had a decreased expression in peripheral organs.
  
  
  CONCLUSIONS
  OX26-pGFAP-IL injected via femoral vein can cross the brain-blood barrier and achieve a specific expression in brain under the control of GFAP promoter. OX26-pGFAP-IL decreases the non-specific expression in peripheral organs and it may be used as an non-viral gene therapy for intra-cranial diseases.
authors.affiliation: Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Peking Union Medical College, Beijing 100730, China.
authors.forename: Hao
authors.initials: H
authors.lastname: Zhao
authors.forename: Ying-jie
authors.initials: YJ
authors.lastname: Zhao
authors.forename: Gui-lin
authors.initials: GL
authors.lastname: Li
authors.forename: Ren-zhi
authors.initials: RZ
authors.lastname: Wang
authors.forename: Yan-guo
authors.initials: YG
authors.lastname: Kong
authors.forename: Ming
authors.initials: M
authors.lastname: Feng
authors.forename: Jun-ji
authors.initials: JJ
authors.lastname: Wei
authors.forename: Shi-fang
authors.initials: SF
authors.lastname: Li
authors.forename: Wen-bin
authors.initials: WB
authors.lastname: Ma
authors.forename: Yi
authors.initials: Y
authors.lastname: Yang
authors.forename: Yong-ning
authors.initials: YN
authors.lastname: Li
mesh_terms: D000818:Animals; D001812:Blood-Brain Barrier; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D007763:Lac Operon / Q000235:genetics*; D008081:Liposomes; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D014161:Transduction, Genetic; D001616:beta-Galactosidase / Q000378:metabolism
chemical_list: D008081:Liposomes; D001616:beta-Galactosidase